Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20016475 | 0.76 | MAPK1 (0.44) | MAPK1 | |
| SCHEMBL19412407 | 0.76 | MMP8 (0.32) | — | |
| SCHEMBL20373458 | 0.75 | — | — | |
| SCHEMBL24337186 | 0.74 | — | — | |
| SCHEMBL756796 | 0.73 | MAPK1 (0.61) | MAPK1HSD17B10 | |
| SCHEMBL4425928 | 0.73 | MAPK1 (0.61) | MAPK1HSD17B10 | |
| SCHEMBL19340475 | 0.72 | ALDH1A1 (0.33) | — | |
| SCHEMBL27824376 | 0.71 | MAPK1 (0.58) | MAPK1HSD17B10 | |
| SCHEMBL15119461 | 0.71 | MAPK1 (0.52) | MAPK1HSD17B10 | |
| SCHEMBL23864858 | 0.71 | MAPK1 (0.38) | MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190022241-A1 | NOVEL SEZ6 MODULATORS AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2019-01-24 | — | — | US | disclosed |
| US-9931421-B2 | Methods of delivering DLL3 antibody drug conjugates | ABBVIE STEMCENTRX LLC (US) | 2018-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190022241-A1 | NOVEL SEZ6 MODULATORS AND METHODS OF USE | IKZF2, BAZ2A, IKZF3 | MAPK1 2975/4885HSD17B10 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.